Lactoferrin-Derived Peptides as a Control Strategy against Skinborne Staphylococcal Biofilms.
Laura QuintieriLeonardo CaputoLinda MonaciMaria Maddalena CavalluzziNunzio DenoraPublished in: Biomedicines (2020)
Coagulase-negative staphylococci (CoNS) widely colonize the human skin and play an active role in host defense. However, these bacteria may cause malodours and increase infection incidence rate in immune-compromised patients and individuals with catheters and implants. CoNS spreading is favored by biofilm formation that also promotes the release of virulence factors and drug resistance. Biofilm control or eradication by antimicrobial peptides (AMPs) represents an attractive strategy which is worth investigating. In this work, bovine lactoferrin (BLF) hydrolysate (HLF) was in vitro evaluated for its antimicrobial and antibiofilm activities against skin-related coagulase negative and positive staphylococci. Despite a minimal inhibitory concentration (MIC) recorded for HLF ranging from 10 to more than 20 mg/mL, a minimal biofilm inhibitory concentration (MIBC) equal to 2.5 mg/mL was found for most target strains. Conversely, MIBC values referred to the individual peptides, LFcinB or LFmpin (herein purified and identified) were significantly lower. Finally, the application of 2.5 mg/mL HLF solution by dipping and spraying on biofilm-attached glass surfaces also caused a high biofilm eradication rate depending on the incubation time, thus attracting interest for future applications in cosmetic formulation for skin care.
Keyphrases
- biofilm formation
- staphylococcus aureus
- candida albicans
- pseudomonas aeruginosa
- escherichia coli
- soft tissue
- methicillin resistant staphylococcus aureus
- cystic fibrosis
- end stage renal disease
- helicobacter pylori infection
- newly diagnosed
- ejection fraction
- antimicrobial resistance
- wound healing
- palliative care
- drug delivery
- risk factors
- chronic pain
- recombinant human
- current status
- patient reported
- innate immune